Wednesday, July 8, 2026

pharma · Critical Limb Ischemia (CLI) · Sarcoma · DSGN

Lxo Ireland Designated

Lxo Ireland Designated is a pharma organization headquartered in CARLSBAD, CA, IE. It trades on NYSE under ticker DSGN. Primary therapeutic focus areas include Critical Limb Ischemia (CLI), Sarcoma, Friedreich Ataxia, HP

CARLSBAD, CA, IE HQ
Public company Type
DSGN · NYSE Ticker
Company details
Clinical program

Hyperbaric bupivacaine+Sufentanil

Approved · small molecule · Anesthesia; Functional

Hyperbaric bupivacaine+Sufentanil for Anesthesia; Functional is a Approved program (small_molecule) at Lxo Ireland Designated Activity Company with 1 ClinicalTrials.gov record(s).

Internal code FPS-CES-2017-01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Lxo Ireland Designated Activity Company
Phase
Approved
Modality
small_molecule
Indication
Anesthesia; Functional
Status
completed
Trials
1